Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC) Meeting Abstract
| Authors: | Abou-Alfa, G. K.; El-Khoueiry, A. B.; Meyer, T.; Rimassa, L.; Merle, P.; Chan, S. L.; Tran, A.; Parnis, F.; Tam, V. C.; Cattan, S.; Markby, D. W.; Clary, D. O.; Cheng, A. L.; Kelley, R. K. |
| Abstract Title: | Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC) |
| Meeting Title: | 69th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting (AASLD) |
| Journal Title: | Hepatology |
| Volume: | 68 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Nov 9-13 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0270-9139 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2018-10-01 |
| Start Page: | 533A |
| End Page: | 534A |
| Language: | English |
| ACCESSION: | WOS:000446020501126 |
| PROVIDER: | wos |
| DOI: | 10.1002/hep.30257 |
| Notes: | Meeting Abstract: 910 -- Source: Wos |
